



(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Abstract

(51) Int Cl.:
C12N 15/09 ^(2006.01) **A61K 31/7088** ^(2006.01)
A61K 48/00 ^(2006.01) **C12N 15/113** ^(2010.01)
G01N 33/53 ^(2006.01)

(48) Corrigendum issued on:
25.06.2014 Bulletin 2014/26

(86) International application number:
PCT/JP2012/064276

(43) Date of publication:
09.04.2014 Bulletin 2014/15

(87) International publication number:
WO 2012/165616 (06.12.2012 Gazette 2012/49)

(21) Application number: **12792620.2**

(22) Date of filing: **01.06.2012**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **03.06.2011 JP 2011125734**

(71) Applicant: **National University Corporation**
Hokkaido University
Sapporo-shi, Hokkaido 060-0808 (JP)

(72) Inventors:
• **MATSUDA Akira**
Sapporo-shi
Hokkaido 060-0808 (JP)
• **TAKAHASHI Mayumi**
Sapporo-shi
Hokkaido 060-0808 (JP)

(74) Representative: **Katzmeyer, Michael**
v. Bezold & Partner
Patentanwälte
Akademiestrasse 7
80799 München (DE)

(54) **OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PHARMACEUTICAL COMPOSITION FOR DIAGNOSIS, AND OLIGONUCLEOTIDE DERIVATIVE FOR REGULATION OF miRNA FUNCTION**

(57) An oligonucleotide derivative comprises repeating structural units represented by the following general formula (wherein B represents adenine, guanine, cytosine, or uracil; X represents a sulfur atom or an oxygen atom; n represents an integer of 6 to 60; and B and X are independently represented in each of the repeating structural units), wherein X is a sulfur atom in at least one of the repeating structural units represented by the general formula:




FIG. 9

EVALUATION OF ACTIVITIES OF AMOs 122

